BR112022025632A2 - Anticorpos anti-pd-1 e proteínas de fusão - Google Patents
Anticorpos anti-pd-1 e proteínas de fusãoInfo
- Publication number
- BR112022025632A2 BR112022025632A2 BR112022025632A BR112022025632A BR112022025632A2 BR 112022025632 A2 BR112022025632 A2 BR 112022025632A2 BR 112022025632 A BR112022025632 A BR 112022025632A BR 112022025632 A BR112022025632 A BR 112022025632A BR 112022025632 A2 BR112022025632 A2 BR 112022025632A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- fusion proteins
- methods
- cell
- binding
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 3
- 108020001507 fusion proteins Proteins 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000003915 cell function Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000000822 natural killer cell Anatomy 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
ANTICORPOS ANTI-PD-1 E PROTEÍNAS DE FUSÃO. A presente invenção refere-se a anticorpos recombinantes, fragmentos de ligação de antígeno e as proteínas de fusão dos mesmos úteis para a ligação e a morte 1 programada (PD-1), moléculas de ácido nucleico que codificam os mesmos e as suas composições terapêuticas, bem como aos métodos de uso de tais anticorpos, incluindo métodos para realçar a função de células T e células NK para aumentar a imunidade das células e mediada por citocina e métodos de tratamento de vários distúrbios relacionados à disfunção imune incluindo o câncer e doenças infecciosas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063043114P | 2020-06-23 | 2020-06-23 | |
US202063111459P | 2020-11-09 | 2020-11-09 | |
PCT/US2021/038740 WO2021262880A2 (en) | 2020-06-23 | 2021-06-23 | Anti-pd-1 antibodies and fusion proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022025632A2 true BR112022025632A2 (pt) | 2023-01-17 |
Family
ID=79282816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022025632A BR112022025632A2 (pt) | 2020-06-23 | 2021-06-23 | Anticorpos anti-pd-1 e proteínas de fusão |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230416363A1 (pt) |
EP (1) | EP4168124A2 (pt) |
JP (1) | JP2023531920A (pt) |
KR (1) | KR20230027267A (pt) |
CN (1) | CN116194471A (pt) |
AU (1) | AU2021296437A1 (pt) |
BR (1) | BR112022025632A2 (pt) |
CA (1) | CA3184746A1 (pt) |
CO (1) | CO2022018053A2 (pt) |
IL (1) | IL299238A (pt) |
MX (1) | MX2022016588A (pt) |
WO (1) | WO2021262880A2 (pt) |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL137121A0 (en) * | 1998-10-30 | 2001-06-14 | Miller Jonathan L | Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein ib alpha |
GB0816461D0 (en) * | 2008-09-09 | 2008-10-15 | Univ Manchester | Biomass |
MX2012011986A (es) * | 2010-04-15 | 2013-03-05 | Amgen Inc | RECEPTOR FGF HUMANO Y PROTEINAS ENLAZADAS A ß-KLOTHO. |
EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
BR112014003769B1 (pt) * | 2011-08-23 | 2022-05-10 | Roche Glycart Ag | Molécula de ligação ao antígeno biespecífica ativadora de célula t, método de produção da molécula de ligação ao antígeno biespecífica ativadora de célula t, composição farmacêutica e uso da molécula de ligação ao antígeno biespecífica ativadora de célula t |
MX2014002996A (es) * | 2011-09-23 | 2014-05-28 | Roche Glycart Ag | Anticuerpos anti - egfr/anti - igf-1r bisespecificos. |
CN109705218B (zh) * | 2012-08-09 | 2022-07-19 | 罗切格利卡特公司 | Asgpr抗体及其用途 |
EP3027649B1 (en) * | 2013-08-01 | 2020-04-01 | F.Hoffmann-La Roche Ag | Tnfa-il-17 bispecific antibodies |
US8945560B1 (en) * | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
PL3094351T3 (pl) * | 2014-01-15 | 2022-06-27 | Kadmon Corporation, Llc | Środki immunomodulujące |
CN114751989A (zh) * | 2015-03-31 | 2022-07-15 | 豪夫迈·罗氏有限公司 | 包含三聚体tnf家族配体的抗原结合分子 |
CN109071652B (zh) * | 2016-05-11 | 2022-09-23 | 豪夫迈·罗氏有限公司 | 包含tnf家族配体三聚体和生腱蛋白结合模块的抗原结合分子 |
MY195110A (en) * | 2016-11-02 | 2023-01-10 | Jounce Therapeutics Inc | Antibodies to PD-1 and uses Thereof |
JP2020529832A (ja) * | 2017-06-30 | 2020-10-15 | ゼンコア インコーポレイテッド | IL−15/IL−15Rαおよび抗原結合ドメインを含む標的化ヘテロダイマーFc融合タンパク質 |
GB201803745D0 (en) * | 2018-03-08 | 2018-04-25 | Ultrahuman Eight Ltd | PD1 binding agents |
US11524991B2 (en) * | 2018-04-18 | 2022-12-13 | Xencor, Inc. | PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof |
-
2021
- 2021-06-23 KR KR1020237002551A patent/KR20230027267A/ko unknown
- 2021-06-23 CN CN202180050584.1A patent/CN116194471A/zh active Pending
- 2021-06-23 MX MX2022016588A patent/MX2022016588A/es unknown
- 2021-06-23 BR BR112022025632A patent/BR112022025632A2/pt unknown
- 2021-06-23 CA CA3184746A patent/CA3184746A1/en active Pending
- 2021-06-23 JP JP2022578618A patent/JP2023531920A/ja active Pending
- 2021-06-23 WO PCT/US2021/038740 patent/WO2021262880A2/en active Application Filing
- 2021-06-23 IL IL299238A patent/IL299238A/en unknown
- 2021-06-23 AU AU2021296437A patent/AU2021296437A1/en active Pending
- 2021-06-23 EP EP21828684.7A patent/EP4168124A2/en active Pending
- 2021-06-23 US US18/011,878 patent/US20230416363A1/en active Pending
-
2022
- 2022-12-13 CO CONC2022/0018053A patent/CO2022018053A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20230416363A1 (en) | 2023-12-28 |
CA3184746A1 (en) | 2021-12-30 |
AU2021296437A1 (en) | 2023-02-23 |
MX2022016588A (es) | 2023-03-15 |
WO2021262880A3 (en) | 2022-02-17 |
IL299238A (en) | 2023-02-01 |
WO2021262880A2 (en) | 2021-12-30 |
EP4168124A2 (en) | 2023-04-26 |
CN116194471A (zh) | 2023-05-30 |
KR20230027267A (ko) | 2023-02-27 |
CO2022018053A2 (es) | 2022-12-20 |
JP2023531920A (ja) | 2023-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20181044A1 (es) | Anticuerpos anti-pd-1 y composiciones | |
BR112018068189A2 (pt) | proteínas de ligação induzíveis e métodos de uso | |
EA201792573A1 (ru) | Триспецифические связанные белки и способы их применения | |
CO2018012415A2 (es) | Proteínas de unión específica y usos de las mismas | |
BR112022014667A2 (pt) | Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos | |
BR112021005769A2 (pt) | proteínas de ligação a dll3 e métodos de uso | |
BR112019008010A2 (pt) | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica | |
EA201892522A1 (ru) | Днк-моноклональные антитела, нацеленные на молекулы контрольных точек | |
PE20190911A1 (es) | Composiciones y anticuerpos anti-lag-3 | |
BR112018012352A2 (pt) | anticorpos anti-lag3 e fragmentos de ligação ao antígeno | |
MX2021011697A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123. | |
BRPI0717363B8 (pt) | imunoglobina humanizada que liga especificamente cd20, composição, vetor recombinante, métodos para obter uma célula hospedeira, de produção de uma imunoglobina que liga especificamente cd20, in viro para inibir o crescimento ou diferenciação de uma célula b humana normal e usos de imunoglobina e de uma quantidade efetiva de imunoglobina | |
Pereira et al. | Purification and characterization of the lectin from taro (Colocasia esculenta) and its effect on mouse splenocyte proliferation in vitro and in vivo | |
MX2023002945A (es) | Moléculas multiespecíficas con direccionamiento inmunitario y usos de estas. | |
BR112021016791A2 (pt) | Proteínas de ligação de antígenos que se ligam a bcma | |
BR112022022503A2 (pt) | Anticorpos neutralizantes que se ligam à proteína s de sars-cov-2 | |
BR112022009273A2 (pt) | Imunoglobulinas modificadas para direcionar depósitos amiloides | |
EA202192907A1 (ru) | Моноклональное антитело, которое специфически связывается с gitr | |
BR112022025856A2 (pt) | Anticorpo que se liga a cd3 e cd19, polinucleotídeo isolado, célula hospedeira, método de produção de um anticorpo que se liga a cd3 e cd19, composição farmacêutica, uso do anticorpo, método para tratar uma doença em um indivíduo e invenção | |
PE20211792A1 (es) | Anticuerpos monoclonales que se unen especificamene a la region beta de la familia trbv-9 del receptor de celulas t humano, y los metodos para su uso | |
MX2023005386A (es) | Anticuerpos monoclonales dirigidos contra la proteina de muerte programada-1 y su uso en medicina. | |
BR112022025632A2 (pt) | Anticorpos anti-pd-1 e proteínas de fusão | |
EA202192488A1 (ru) | Антитела против tsg-6 и их применения | |
BR112022020716A2 (pt) | Anticorpos anti-tumor associados ao antígeno e usos dos mesmos | |
BR112017021830A2 (pt) | ?anticorpo monoclonal que neutraliza staphylococcus aureus, seu uso médico ou diagnóstico, uma preparação farmacêutica ou diagnóstica, moléculas de ácido nucleico que codificam o anticorpo e um método para produzir o anticorpo? |